RIGL News and Press, Rigel Pharmaceuticals Inc. From 10/08/25

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS PR Newswire Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS ...

2025-09-25 22:53:49 ET Introduction Rigel Pharmaceuticals (RIGL) is a commercial-stage biotechnology company that is developing oral small-molecule kinase inhibitors, which are used to help treat blood disorders and certain cancers. Despite having three commercialized products a...

2025-09-21 10:38:57 ET This article discusses a quantitative system that identifies growth leaders with strong momentum at both the fundamental level and in terms of price action. This type of system can produce substantial alpha over the long term.... Read the full article on See...

Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders...

2025-08-15 15:00:59 ET More on the markets Forget The September Rate Cut AAII Sentiment Survey: Optimism Slides Slowing Growth And Rising Federal Debt Complicate U.S. Economic Outlook Trump-Putin summit: What to expect AI-linked investment lifted GDP ...

2025-08-13 23:58:40 ET It has been a few months since my last Rigel Pharmaceuticals ( RIGL ) article , where I was bullish about their strong momentum coming out of Q1 with a 68% year-over-year revenue jump, as TAVALISSE, GAVRETO, and REZLIDHIA showing prospects for sustained growth...

2025-08-05 20:02:45 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Historical earnings data for Rigel Pharmaceuticals Financial information for ...

2025-08-05 20:02:09 ET Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Conference Call August 05, 2025, 04:30 PM ET Company Participants David A. Santos - Executive VP & Chief Commercial Officer Dean L. Schorno - Executive VP & CFO Lisa Rojkjaer - Exe...

2025-08-05 16:05:18 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Historical earnings data for Rigel Pharmaceuticals Financial information for Rigel P...

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire Second quarter 2025 total revenue of approximately $101.7 million , which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 m...